NCT06562985View on ClinicalTrials.gov

A Study to Learn About How Safe BAY3018250 is and What Happens to it in Healthy Japanese Men and Adult Participants Aged 18 to 55 Years

PHASE1CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

September 18, 2024

Primary Completion Date

January 6, 2025

Study Completion Date

January 6, 2025

Conditions
Acute Venous and Arterial Thrombotic and Thromboembolic EventsHealthy Volunteers
Interventions
DRUG

BAY3018250 Dose 1

Infusion, single dose

DRUG

Placebo

BAY3018250 matching placebo, infusion

DRUG

Placebo

BAY3018250 matching placebo, injection

DRUG

BAY3018250 Dose 2 infusion

Infusion, single dose

DRUG

BAY3018250 Dose 2 injection

Injection, single dose

Trial Locations (1)

90720

Collaborative Neuroscience Research, LLC, Los Alamitos

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY